BioNTech SE (BSP:B1NT34) FFO


BSP:B1NT34 BioNTech SE BSP:B1NT34
53 GF Score
Price R$29.34
GF Value R$27.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE FFO?

FFO (Funds from operations) only applies to REITs.

BSP:B1NT34
53GF Score
BioNTech SE BSP:B1NT34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioNTech SE (BSP:B1NT34) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of R$29.34 is trading 7.1% above its estimated GF Value™ of R$27.40. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for BSP:B1NT34:

  • FFO:
  • GF Value™: R$27.40 vs. price of R$29.34 (7.1% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the BSP:B1NT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
53GF Score

Get the complete analysis for BSP:B1NT34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$29.34
Price
R$27.40
GF Value